Description

The effective translation of insights gained from biomedical research into improved human health is a global priority. To this end, Elsevier has looked to the leadership of its two leading brands, Cell Press and The Lancet, to guide the launch of a new comprehensive, online-only open access Elsevier journal, EBioMedicine, focused on forming a community that spans this interface and creates a valuable opportunity for dialogue and collaboration between their respective audiences.

As the communities that border this interface are large and diverse, the scope of EBioMedicine will cover the entire breadth of translational and clinical research within all disciplines of life and health sciences, ranging from basic science to clinical and public/global health science. The journal will also place a high priority on rapid publication. The journal seeks to publish a broad range of research study types, from experimental findings, critical analyses, methodological & technical innovations, and hypotheses to observational epidemiological studies, clinical trials, meta-analyses, and study protocols. In addition, EBioMedicine will publish commentaries, reviews, and viewpoints that enhance the accessibility and applicability of basic research findings for health professionals, and promote a better understanding of clinical challenges for biomedical researchers.

In leveraging the editorial leadership from Cell Press and The Lancet together with the publishing expertise of Elsevier to create a unique forum for the reputable and speedy publication of research in life and health sciences, we are committed to facilitating and incentivizing a robust and successful pipeline for improved human health globally.

Abstracting and Indexing

MEDLINE®
EMBASE
ScienceDirect
Scopus
Directory of Open Access Journals (DOAJ)
Emerging Sources Citation Index (ESCI)
PubMed Central
EDITORIAL BOARD

Editors-in-Chief
D. Le
J. Stacey

Scientific Editors
T. Dobie
D. Stuckey

Advisory Board Members
R. Anderson, University of Wisconsin-Madison, Madison, Wisconsin, USA
P.A. Ascierto, National Tumor Institute Fondazione G Pascale, Italy
A. Atala, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
G.S. Baillie, University of Glasgow, Glasgow, Scotland, UK
P.J. Barnes, Imperial College London, London, England, UK
K. Bhakoo, A*STAR, Singapore
M.J. Blaser, New York University (NYU) School of Medicine, New York, New York, USA
B.G. Bruneau, University of California at San Francisco (UCSF), San Francisco, California, USA
F.M. Buonaguro, National Tumor Institute Fondazione G Pascale, Naples, Italy
J. Burn, Newcastle University, Newcastle, England, UK
J. Campisi, Lawrence Berkeley National Laboratory, Novato, California, USA
P. Cani, Université Catholique de Louvain, Brussels, Belgium
X. Cao, Chinese Academy of Medical Sciences, Beijing, China
S. Carmichael, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
K. Chayama, Hiroshima University, Hiroshima, Japan
G. Corradin, Université de Lausanne, Lausanne, Switzerland
M. Cotten, Duke University School of Medicine, Durham, North Carolina, USA
B. Cronstein, NYU School of Medicine, New York, USA
J.F. Cryan, University College Cork, Cork, Ireland
D. de Quervain, Universität Basel, Basel, Switzerland
S.G. Deeks, University of California at San Francisco (UCSF), San Francisco, California, USA
R. DePinho, University of Texas, Houston, Texas, USA
Z. Dong, University of Minnesota, Austin, Minnesota, USA
E. Elliott, The University of Sydney, Sydney, Australia
Z.A. Fayad, Mount Sinai Hospital, New York, New York, USA
R. Frier, University of Cambridge, Cambridge, England, UK
I.H. Frazer, University of Queensland, Woolloongabba, Queensland, Australia
F. Friedman, NIH Bethesda, Bethesda, Maryland, USA
M. Friesen, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
M.E. Gershwin, University of California, Davis, Davis, California, USA
G. Ginsburg, Duke University School of Medicine, Durham, North Carolina, USA
A. Harandi
B.F. Haynes, Duke University Medical Center, Durham, North Carolina, USA
B.T. Hyman, Harvard Medical School, Massachusetts, USA
S.E. Hyman, Harvard University, Cambridge, Massachusetts, USA
K.J. Ishii, Osaka University, Osaka, Japan
B. Kampmann, Imperial College London, London, England, UK
N. W. Keith, University of Glasgow, Lanarkshire, Scotland, UK
A. Khademhosseini, Harvard Medical School, Cambridge, Massachusetts, USA
S. Kumar, University of California, Berkley, California, USA
R. Loomba, University of California at San Diego (UCSD), La Jolla, California, USA
C. Lüscher, Université de Genève, Genève 4, Switzerland
U. Mahmood, Massachusetts General Hospital, Massachusetts, USA
F. Marincola, Sidra Medical & Research Center, Qatar
J. Martel-Pelletier, University of Montreal, Quebec, Canada
J.W. Miller, Harvard Medical School, Boston, Massachusetts, USA
J. Moore, Imperial College London, London, England, UK
L. Muttì, Vercelli/ Borgosesia Hospital, Italy
V. Nizet, UC San Diego School of Medicine, California, USA
J. Noebels, Baylor College of Medicine, Houston, Texas, USA
H. Okano, Keio University, Tokyo, Japan
E. Olson, University of Texas Southwestern Medical Center, Dallas, USA
B. O’Nuallain, Harvard Medical School, Massachusetts, USA
J. O’Shea, National Institute of Arthritis and Musculoskeletal & Skin Diseases (NIAMS), Bethesda, Maryland, USA
M. Pai, McGill University, Montreal, Quebec, Canada
P. Palese, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.
To find out more, please visit the Preparation section below.

INTRODUCTION
Aims & scope
The effective translation of insights gained from biomedical research into improved human health is a global priority. To this end, Elsevier has looked to the leadership of its two leading brands, Cell Press and The Lancet, to guide the launch of a new comprehensive, online-only open access Elsevier journal, EBioMedicine, focused on forming a community that spans this interface and creates a valuable opportunity for dialogue and collaboration between their respective audiences.

As the communities that border this interface are large and diverse, the scope of EBioMedicine will cover the entire breadth of translational and clinical research within all disciplines of life and health sciences, ranging from basic science to clinical and public/global health science. The journal will also place a high priority on rapid publication.

The journal seeks to publish a broad range of research study types, from experimental findings, critical analyses, methodological and technical innovations to observational epidemiological studies, clinical trials and meta-analyses. In addition, EBioMedicine will publish commentaries, reviews and viewpoints that enhance the accessibility and applicability of basic research findings for health professionals, and promote a better understanding of clinical challenges for biomedical researchers.

In leveraging the editorial leadership from Cell Press and The Lancet together with the publishing expertise of Elsevier to create a unique forum for the reputable and speedy publication of research in life and health sciences, we are committed to facilitating and incentivizing a robust and successful pipeline for improved human health globally.

BEFORE YOU BEGIN
The review process
EBioMedicine aims at having a transparent and quick editorial process. Peer review is handled by the editorial team (Dr Julie Stacey, Dr Duc Le, Dr Ted Dobie and Dr Daniel Stuckey). The Editors receive and assesses the manuscripts. Peer review is single blind, with a minimum of two reviews required per article. Once both review reports are received, the Editors make the final decision on a manuscript.

Ethics in publishing
For information on Ethics in publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/journal-authors/ethics. Availability of Materials. By publishing in the journal, the authors agree that, subject to requirements or limitations imposed by laws or governmental regulations, any DNAs, viruses, microbial strains, mutant animal strains, cell lines, antibodies, and similar materials described in the article are available from a national collection or will be made available in a timely fashion, at reasonable cost, and in limited quantities to members of the scientific community for noncommercial purposes. The authors guarantee that they have the authority to comply with this policy either directly or by means of material transfer agreements through the owner.

Human and animal rights
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; Uniform Requirements for manuscripts submitted to Biomedical journals. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
All animal experiments should comply with the **ARRIVE guidelines** and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed.

**Conflict of Interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. Please complete the Author declaration form. See also: http://www.elsevier.com/conflictsofinterest.

**Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see 'Multiple, redundant or concurrent publication' section of our ethics policy for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck.

**Authorship**

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

**Changes to authorship**

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Clinical trial results**

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

**Reporting clinical trials**

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram are available online.

Please see the Checklist Clinical trials and Checklist non-Clinical trials.
**Registration of clinical trials**

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

**Article transfer service**

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information.](#)

**Copyright**

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (see [more information](#) on this). Permitted third party reuse of open access articles is determined by the author's choice of user license.

**Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information.](#)

*Elsevier supports responsible sharing*

Find out how you can share your research published in Elsevier journals.

**Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

**Funding body agreements and policies**

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the Open Access Publication Fee. Details of [existing agreements](#) are available online.

**Open access**

This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following Creative Commons user licenses:

- **Creative Commons Attribution (CC BY)**
  
  Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

- **Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)**
  
  For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.
The open access publication fee for this journal is **USD 3000**, excluding taxes. Learn more about Elsevier's pricing policy: [http://www.elsevier.com/openaccesspricing](http://www.elsevier.com/openaccesspricing).

**Language**

Please write your text in American English. Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](http://www.elsevier.com/webshop/editservices) available from Elsevier's WebShop.

**Informed consent and patient details**

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the [Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals](http://www.elsevier.com/permissions). Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

**Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

**Submit your article**

Please submit your article via [http://ees.elsevier.com/EBIOM](http://ees.elsevier.com/EBIOM).

**Referees**

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our [Support site](http://www.elsevier.com/support). Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

**PREPARATION**

**NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process. As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

**Research papers**

Please see the [Checklist Clinical trials](http://www.elsevier.com/checklists) and [Checklist non-Clinical trials](http://www.elsevier.com/checklists) for detailed guides on individual sections and formatting requirements.

**Review articles**

At *EBioMedicine*, it is our aim to curate concise and informative reviews of topical interest to researchers from both basic science and clinical realms. Reviews should be focused on a specific biomedical topic with timely translational relevance. If you wish to submit a review article, please first contact one of our editors. For more information, please read the attached [guidelines for Review articles](http://www.elsevier.com/checklists).

**Peer review**

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review](http://www.elsevier.com/checklists).
REVISED SUBMISSIONS

Use of word processing software

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

• Title page (article title, full authorship and affiliations, corresponding author contact details)
• Abstract
• Keywords (4–6 keywords)
• Highlights and Research in Context sections
• Introduction
• Materials and Methods
• Results
• Discussion (please make sure Results and Discussion are separate sections, not combined)
• Acknowledgements
• Funding Sources
• Conflicts of Interest
• Author Contributions
• References
• Figure Legends

Please see the Checklist Clinical trials and Checklist non-Clinical trials for detailed guides on individual sections and formatting requirements.

Essential title page information

• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.

• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.
Authors can make use of Elsevier’s Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

**Highlights**
Please provide 2–3 sentences in bulleted format, summarizing the key findings in your paper. Each sentence (bullet) should be less than 125 characters including spaces.

**Research in Context**
Please provide a short paragraph (100 words max) which will help the non-specialist reader understand the most important message from the findings.

In particular, why the findings are relevant to human health (for the more basic research papers), and/or how the findings can help improve our understanding of the disease mechanisms (for the more clinical papers).

This should be written not only for scientists and clinicians, but also for curious members of the general public. Therefore, please use clear and simple language, avoiding jargon and abbreviations.

**Keywords**
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Abbreviations**
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

**Acknowledgements**
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

**Units**
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

**Math formulae**
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

**Artwork**

**Electronic artwork**

**General points**
- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed guide on electronic artwork is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

**Formats**
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
- EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

**AUTHOR INFORMATION PACK  27 Aug 2017   www.elsevier.com/locate/ebiom**
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.

Illustration services
Elsevier's WebShop offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is encouraged.

A DOI can be used to cite and link to electronic articles where an article is in-press and full citation details are not yet known, but the article is available online. A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:
http://open.mendeley.com/use-citation-style/ebiomedicine

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

**Reference style**

**Text:** All citations in the text should refer to:

1. **Single author:** the author's name (without initials, unless there is ambiguity) and the year of publication;
2. **Two authors:** both authors' names and the year of publication;
3. **Three or more authors:** first author's name followed by 'et al.' and the year of publication.

Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically. Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al. (2010) have recently shown ....'

**List:** References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

**Examples:**

Reference to a journal publication:

Reference to a book:

Reference to a chapter in an edited book:

Reference to a website:

Reference to a dataset:

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 150 MB in total. Any single file should not exceed 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

RESEARCH DATA
Reagent identification
In an effort to support reproducibility, we request that you please—whenever available—include a Research Resource Identifier (RRID) for any biological reagents used in the study. These include, for example, antibodies, genetically modified organisms and cell lines.

To find an RRID, please visit https://scicrunch.org/resources and enter your search term(s) there. For search tips and help, contact rii-help@scicrunch.org.

Once you have located an RRID, please insert "RRID:" plus the identifier in the appropriate location in the manuscript. For example:
Antibodies: "Sections were stained with a rabbit polyclonal antibody against ERK1 (Abgent Cat# AP7251E, RRID: AB_2140114)."
Genetically modified organisms: "Subjects in this study were Fgf9Eks/Fgf9+ mice (RRID: MGI_3840442) ..."

Data Deposition, Database Linking, and Materials SharingR
It is expected that the authors will be willing to distribute any new reagents described in the Methods section of the manuscript to qualified researchers for their own use upon written request. Data sets must be made freely available to readers from the date of publication and must be provided to editors and peer reviewers at submission for the purposes of evaluating the manuscript. If there are restrictions to the availability of any materials or data, these must be disclosed in the cover letter and in the Methods at the time of submission.

Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers one-click access to underlying data that give them a better understanding of the research described. For more information, visit the database linking page. For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.
Newly described data sets must be deposited to a public repository, and accession numbers must be clearly identified under a separate subheading at the end of the Methods section. Please refer to relevant database identifiers using the following format in your article: "Database: xxxx" for single accession numbers and "Database: xxxx, yyyy, zzzz" for multiple accession numbers (e.g., "Genbank: NM_000492"; "GEO: GSE6364"; "PDB: 1TUP, 1KW4, 3H5X"). Examples of appropriate public repositories are:

- DNA and RNA sequences: GenBank, EMBL-EBI, DDBJ
- Protein sequence: EMBL-EBI, Protein Data Bank
- Microarray and deep sequencing data: GEO, ArrayExpress
- SNPs and CNVs: dbSNP, DGVa, dbVAR
- Genotypes and phenotypes: dbGaP
- Proteomics data: PRIDE, PeptideAtlas
- Protein interaction data: IMEx consortium of databases
- Chemical compound: PubChem
- Brain imaging data: OpenfMRI repository, Neurovault repository

Where there is no public repository and if the data sets are too large to submit to the journal as Supplementary data, authors should either consult the journal editorial office for advice or provide five separate copies of these data to the editors in an appropriate format (for example, CD or DVD) for the purposes of peer review.

**ARTICLE ENRICHMENTS**

**Google Maps and KML files**
KML (Keyhole Markup Language) files (optional): You can enrich your online articles by providing KML or KMZ files which will be visualized using Google maps. The KML or KMZ files can be uploaded in our online submission system. KML is an XML schema for expressing geographic annotation and visualization within Internet-based Earth browsers. Elsevier will generate Google Maps from the submitted KML files and include these in the article when published online. Submitted KML files will also be available for downloading from your online article on ScienceDirect. More information.

**Chemical Compound Viewer (Reaxys)**
You can enrich your article with visual representations, links and details for those chemical structures that you define as the main chemical compounds described. Please follow the instructions to learn how to do this.

**Interactive Phylogenetic Trees**
You can enrich your online articles by providing phylogenetic tree data files (optional) in Newick or NeXML format, which will be visualized using the interactive tree viewer embedded within the online article. Using the viewer it will be possible to zoom into certain tree areas, change the tree layout, search within the tree, and collapse/expand tree nodes and branches. Submitted tree files will also be available for downloading from your online article on ScienceDirect. Each tree must be contained in an individual data file before being uploaded separately to the online submission system, via the 'phylogenetic tree data' submission category. Newick files must have the extension .new or .nwk (note that a semicolon is needed to end the tree). Please do not enclose comments in Newick files and also delete any artificial line breaks within the tree data because these will stop the tree from showing. For NeXML, the file extension should be .xml. Please do not enclose comments in the file. Tree data submitted with other file extensions will not be processed. Please make sure that you validate your Newick/NeXML files prior to submission. More information.

**Antibody data**
Antibody Data is the reference application linking to information about the antibodies mentioned in the article, based on the NIF Antibody Registry. Authors are encouraged to include relevant antibody identifiers in their articles (e.g. Antibody Registry: AB_878537 or RRID: AB_878537) if appropriate. More information.

**Interactive MATLAB Figure Viewer**
This journal features the Interactive MATLAB Figure Viewer, allowing you to display figures created in MATLAB in the .FIG format in an interactive viewer next to the article. More information and submission instructions.
**3D molecular models**

You can enrich your online articles by providing 3D molecular models (optional) in PDB, PSE or MOL/MOL2 format, which will be visualized using the interactive viewer embedded within the article. Using the viewer, it will be possible to zoom into the model, rotate and pan the model, and change display settings. Submitted models will also be available for downloading from your online article on ScienceDirect. Each molecular model will have to be uploaded to the online submission system separately, via the '3D molecular models' submission category. More information.

**3D neuroimaging**

You can enrich your online articles by providing 3D neuroimaging data in NIfTI format. This will be visualized for readers using the interactive viewer embedded within your article, and will enable them to: browse through available neuroimaging datasets; zoom, rotate and pan the 3D brain reconstruction; cut through the volume; change opacity and color mapping; switch between 3D and 2D projected views; and download the data. The viewer supports both single (.nii) and dual (.hdr and .img) NIfTI file formats. Recommended size of a single uncompressed dataset is maximum 150 MB. Multiple datasets can be submitted. Each dataset will have to be zipped and uploaded to the online submission system via the '3D neuroimaging data' submission category. Please provide a short informative description for each dataset by filling in the 'Description' field when uploading a dataset. Note: all datasets will be available for downloading from the online article on ScienceDirect. If you have concerns about your data being downloadable, please provide a video instead. More information.

**3D radiological data**

You can enrich your online article by providing 3D radiological data in DICOM format. Radiological data will be visualized for readers using the interactive viewer embedded within your article, and will enable them to: browse through available radiological datasets; explore radiological data as 2D series, 2D orthogonal MPR, 3D volume rendering and 3D MIP; zoom, rotate and pan 3D reconstructions; cut through the volume; change opacity and threshold level; and download the data. Multiple datasets can be submitted. Each dataset will have to be zipped and uploaded to the online submission system via the '3D radiological data' submission category. The recommended size of a single uncompressed dataset is 200 MB or less. Please provide a short informative description for each dataset by filling in the 'Description' field when uploading each ZIP file. Note: all datasets will be available for download from the online article on ScienceDirect. So please ensure that all DICOM files are anonymized prior to submission. More information.

**Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

**Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address
- Telephone

All necessary files have been uploaded, and contain:
- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations:
- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)

For any further information please visit our customer support site at [http://support.elsevier.com](http://support.elsevier.com).

**AFTER ACCEPTANCE**

**Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF. We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will be notified and receive a link to the published version of the open access article on ScienceDirect. This link is in the form of an article DOI link which can be shared via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Webshop. Authors requiring printed copies of multiple articles may use Elsevier Webshop's 'Create Your Own Book' service to collate multiple articles within a single cover.

AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch. You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2014 Elsevier | http://www.elsevier.com